Assessing clinicians' perspectives about the identification and management of antipsychotic medication side-effects: Psychometric evaluation of a survey questionnaire

International Journal of Mental Health Nursing

Volumn 25, Issue 2, 2016, Pages 171-179

  Stomski, Norman J ^a   Morrison, Paul ^a   Meehan, Tom ^b  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antipsychotic medication; Mental health; Side effect; Survey

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AUSTRALIA; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MIDDLE AGED; PSYCHIATRIC NURSING; PSYCHOLOGY; PSYCHOMETRY; PSYCHOTIC DISORDERS; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; VALIDATION STUDY;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC NURSING; PSYCHOMETRICS; PSYCHOTIC DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 84957602807     PISSN: 14458330     EISSN: 14470349     Source Type: Journal    
DOI: 10.1111/inm.12216     Document Type: Article

References (49)

1. Ascher-Svanum, H., Faries, D. E., Zhu, B., Ernst, F. R., Swartz, M. S. & Swanson, J. W. (2006). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry, 67, 453-460.
2. Australian Institute of Health and Welfare. (2014). Mental health nursing workforce. [Cited 1 May 2015]. Available at: http://mhsa.aihw.gov.au/resources/workforce/mental-health-nursing-workforce/
3. Bannon, W. Jr. (2015). Missing data within a quantitative research study: How to assess it, treat it, and why you should care. Journal of the American Association of Nurse Practitioners, 27, 230-232.
4. Barnes, T. R., Paton, C., Cavanagh, M. R., Hancock, E., Taylor, D. M. & Health, U. K. Prescribing Observatory for Mental (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin, 33, 1397-1403.
5. Bullock, S. & Manias, E. (2002). The educational preparation of undergraduate nursing students in pharmacology: a survey of lecturers' perceptions and experiences. Journal of Advanced Nursing, 40, 7-16.
6. Bressington, D., Mui, J. & Gray, R. (2013). Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study. International Journal of Mental Health Nursing, 22, 35-46.
7. Chouinard, G. & Margolese, H. C. (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research, 76(2-3), 247-265.
8. Cochran, W. G. (1977). Sampling techniques, 3rd ednNew York: John Wiley & Sons.
9. Comrey, A. L. & Lee, H. B. (1992). A first course in factor analysis, 2nd ednHillsdale, N.J.: L. Erlbaum Associates.
10. Coombs, T., Deane, F. P., Lambert, G. & Griffiths, R. (2003). What influences patients' medication adherence? Mental health nurse perspectives and a need for education and training. Int J Ment Health Nurs, 12, 148-152.
11. Costello, A. B. & Osborne, J. W. (2005). Best Practices in Exploratory Factor Analysis: Four Recommendations for Getting the Most From Your Analysis. Practical Assessment, Research & Evaluation, 10, 1-9.
12. Dassori, A. M., Miller, A. L. & Weiden, P. J. (2003). The approaches to schizophrenia communication (ASC) tool: including the patient perspective in treatment. Disease Management & Health Outcomes, 11, 699-708.
13. De Hert, M., Cohen, D., Bobes, J., et al. (2011). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 10, 138-151.
14. Forsner, T., Hansson, J., Brommels, M., Wistedt, A. A. & Forsell, Y. (2010). Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers. BMC Psychiatry, 10, 8.
15. Franklin, S. B., Gibson, D. J., Robertson, P. A., Pohlmann, J. T. & Fralish, J. S. (1995). Parallel Analysis: a Method for Determining Significant Principal Components. Journal of Vegetation Science, 6, 99-106.
16. Gray, R., Wykes, T., Parr, A.-M., Hails, E. & Gournay, K. (2001). The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice. Journal of Psychiatric and Mental Health Nursing, 8(3), 191-196.
17. Haddad, P. M., Brain, C. & Scott, J. (2014). Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures, 5, 43-62.
18. Haddad, P. M., Das, A., Keyhani, S. & Chaudhry, I. B. (2012). Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. Journal of Psychopharmacology, 26, 15-26.
19. Hair, J. F. (2010). Multivariate data analysis, 7th ednUpper Saddle River, NJ: Prentice Hall.
20. Hellewell, J. S. E. (1999). Do we know what matters to our patients. Clear Perspectives: Management Issues in Schizophrenia, 2, 1-4.
21. Herings, R. M. & Erkens, J. A. (2003). Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiology and Drug Safety, 12, 423-424.
22. Howard, P. B., El-Mallakh, P., Miller, A. L., et al. (2009). Fidelity to a Medication Management Evidence-Based Practice in the Treatment of Schizophrenia. Psychiatric Services, 60, 929-935.
23. IBM Corp (2012). IBM SPSS Statistics for Mackintosh, Version 21.0. Armonk, NY: IBM Corp.
24. Lambert, M., Conus, P., Eide, P., et al. (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry, 19, 415-422.
25. Ledesma, R. D. & Valero-Mora, P. (2007). Determining the Number of Factors to Retain in EFA: an easy-touse computer program for carrying out Parallel Analysis. Practical Assessment, Research & Evaluation, 12, 1-11.
26. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C. & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373(9657), 31-41.
27. Lieberman, J. A. (2007). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. Journal of Clinical Psychiatry, 68e04.
28. Lynn, M. R. (1986). Determination and quantification of content validity. Nursing Research, 35, 382-385.
29. Mackin, P., Bishop, D. R. & Watkinson, H. M. (2007). A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry, 7, 28.
30. Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334-1349.
31. McCann, T. V., Boardman, G., Clark, E. & Lu, S. (2008). Risk profiles for non-adherence to antipsychotic medications. Journal of Psychiatric and Mental Health Nursing, 15, 622-629.
32. Miller, D. D., Caroff, S. N., Davis, S. M., et al. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry, 193, 279-288.
33. Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U. & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine, 42, 125-147.
34. Morrison, P., Meehan, T. & Stomski, N. J. (2015a). Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side-effects. International Journal of Mental Health Nursing, 24, 104-111.
35. Morrison, P., Meehan, T. & Stomski, N. J. (2015b). Australian mental health staff response to antipsychotic medication side effects - the perceptions of consumers. Advances in Mental Health, [EPub-Ahead of Print]. DOI: 10.1080/18387357.2015.1080651.
36. Morrison, P., Meehan, T. & Stomski, N. J. (2015c). Living with antipsychotic medication side-effects: The experience of Australian mental health consumers. International Journal of Mental Health Nursing, 24, 253-261.
37. Morrison, P. & Stomski, N. J. (2015). Embracing participation in mental health research: conducting authentic interviews. Qualitative Research Journal, 15, 47-60.
38. Mutsatsa, S. H., Joyce, E. M., Hutton, S. B., et al. (2003). Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandanavica, 108, 439-446.
39. Nguyen, D., Brakoulias, V. & Boyce, P. (2009). An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry, 17, 295-299.
40. Novick, D., Haro, J. M., Suarez, D., Perez, V., Dittmann, R. W. & Haddad, P. M. (2010). Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 176, 109-113.
41. Polit, D. F. & Beck, C. T. (2006). The content validity index: are you sure you know what's being reported? Critique and recommendations. Research in Nursing & Health, 29, 489-497.
42. Saha, S., Chant, D. & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry, 64, 1123-1131.
43. Stomski, N. J., Morrison, P. & Meyer, A. (2015). Antipsychotic medication side effect assessment tools: A systematic review. The Australian and New Zealand Journal of Psychiatry. DOI:10.1177/0004867415608244.
44. Streiner, D. L. & Norman, G. R. (2008). Health measurement scales: a practical guide to their development and use, 4th edn. Oxford: New York: Oxford University Press.
45. Ward, A., Ishak, K., Proskorovsky, I. & Caro, J. (2006). Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clinical Therapeutics, 28, 1912-1921.
46. Wolters, H. A., Knegtering, H., van den Bosch, R. J. & Wiersma, D. (2009). Effects and side effects of antipsychotic treatment in schizophrenia: Pros and cons of available self-rating scales. Schizophrenia Research, 112, 114-118.
47. Wong, M. M., Chen, E. Y., Lui, S. S. & Tso, S. (2011). Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clinical Schizophrenia & Related Psychoses, 5, 135-141.
48. Worthington, R. L. & Whittaker, T. A. (2006). Scale development research: A content analysis and recommendations for best practices. The Counselling Psychologist, 34, 806-838.
49. Zwick, W. R. & Velicer, W. F. (1986). Comparison of five rules for determining the number of components to retain. Psychological Bulletin, 99, 432-442.